FlowMedica


		Targeted Renal Therapy Targeted Renal Therapy (TRT™), the delivery of therapeutic agents directly to the kidneys via the renal arteries, is an approach pioneered by FlowMedica. TRT is an alternative to the standard delivery method of systemic intravenous (IV) infusion to address kidney dysfunction related to a number of conditions, including cardiovascular, endovascular, and surgical procedures and diseases. >>


		Benephit® Infusion System Family The Benephit® CV Infusion System, Benephit PV Infusion System and Benephit XT Infusion System are proprietary selective-infusion catheter systems designed for implementing TRT directly into both renal arteries through a single catheter simultaneously. The Benephit CV, PV,and XT Infusion Systems are FDA 510(k)-cleared and the Benephit CV and PV Infusion System bear the CE Marking. All systems are indicated for the "infusion of physician-specified agents in the peripheral vasculature including, but not limited to, the renal arteries." >>

January 20 - 24, 2008

International Symposium on Endovascular Therapy (ISET) - Hollywood, FL >>

February 25 - 28, 2008

International Conference on Continuous Renal Replacement Therapy (CRRT) - San Diego, CA >>

March 15 - 20, 2008

Society of Radiology (SIR) - Washington, DC >>

June 10-12 , 2008

Acute Kidney Injury Network (AKIN) - Bethesda, MD >>